Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults

References

• Ward NA. Poliomyelitis: a review. Trop Doct. 1983;13:21–28. doi:10.1177/004947558301300108.
   PubMed Web of Science ®Google Scholar
• WHA 41st World Health Assembly. Global eradication of poliomyelitis by 2000. Geneva World Health Organization [resolution WHA41.28]. 1988 [accessed 2020 Mar 16]. http://polioeradication.org/wp-content/uploads/2016/07/19880513_resolution-2.pdf.
   Google Scholar
• Khan F, Datta SD, Quddus A, Vertefeuille JF, Burns CC, Jorba J, Wassilak SGF. Progress toward polio eradication — worldwide, January 2016–March 2018. MMWR Morb Mortal Wkly Rep. 2018;67(18):524–28. doi:10.15585/mmwr.mm6718a4.
   PubMed Web of Science ®Google Scholar
• Zaffran M, McGovern M, Hossaini R, Martin R, Wenger J. The polio endgame: securing a world free of all polioviruses. Lancet. 2018;391(10115):11–13. doi:10.1016/S0140-6736(17)32442-X.
   PubMed Web of Science ®Google Scholar
• World Health organization. Global polio eradication initiative. Polio this week. 2020 [accessed 2020 Mar 16]. http://polioeradication.org/polio-today/polio-now/this-week/.
   Google Scholar
• Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(Suppl 1):S459–464. doi:10.1093/infdis/jiu128.
   PubMedGoogle Scholar
• World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication. Geneva: World Health Organization [resolution WHA61.1]. 2008 [accessed 2020 Mar 16]. http://polioeradication.org/wp-content/uploads/2016/07/WHA61_Resolution_English.pdf.
   Google Scholar
• Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine — worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016;65(35):934–38. doi:10.15585/mmwr.mm6535a3.
   PubMed Web of Science ®Google Scholar
• Global Polio Eradication Initiative. Polio eradication and endgame strategic plan 2013–2018. 2013 [accessed 2020 Mar 16]. http://polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf.
   Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, November 2012 – conclusions and recommendations. Polio eradication. Weekly Epidemiological Rec 2013;88:5–7.
   Google Scholar
• World Health Organization. Polio vaccines: WHO position paper - March 2016. Weekly Epidemiological Rec 2016;12:145–68.
   Google Scholar
• Global Polio Eradication Initiative. Polio post-certification strategy: a risk mitigation strategy for a polio-free world. Geneva: World Health Organization. License: CC BY-NC-SA 3.0 IGO. 2018 [accessed 2020 Mar 16]. http://polioeradication.org/wp-content/uploads/2018/04/polio-post-certification-strategy-20180424-2.pdf.
   Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2017 – conclusions and recommendations. Polio Eradication. Weekly Epidemiological Rec 2017;92:308–10.
   Google Scholar
• Okayasu H, Sein C, Hamidi A, Bakker WAM, Sutter RW. Development of inactivated poliovirus vaccine from Sabin strains: a progress report. Biologicals. 2016;44(6):581–87. doi:10.1016/j.biologicals.2016.08.005.
   PubMed Web of Science ®Google Scholar
• Knowlson S, Burlison J, Giles E, Fox H, Macadam AJ, Minor PD. New strains intended for the production of inactivated polio vaccine at low-containment after eradication. PLoS Pathog. 2015;11(12):e1005316. doi:10.1371/journal.ppat.1005316.
   PubMed Web of Science ®Google Scholar
• Okayasu H, Sein C, Chang Blanc D, Gonzalez AR, Zehrung D, Jarrahian C, Macklin G, Sutter RW. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose-sparing option for polio immunization. J Infect Dis. 2017;216(Suppl 1):S161–167. doi:10.1093/infdis/jix038.
   PubMedGoogle Scholar
• Rivera L, Pedersen RS, Peña L, Olsen KJ, Andreasen LV, Kromann I, Nielsen PI, Sørensen C, Dietrich J, Bandyopadhyay AS, et al. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. Lancet Infect Dis. 2017;17(7):745–53. doi:10.1016/S1473-3099(17)30177-9.
   PubMed Web of Science ®Google Scholar
• Verdijk P, Rots NY, MGCT VO, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WAM. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults. Vaccine. 2013;31(47):5531–36. doi:10.1016/j.vaccine.2013.09.021.
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Fonseca M, Alemañi N, Diaza M, Martinez Y, Garcia G, Okayasu H, Burton A, Bakker WAM, et al. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I trial in healthy adults in Cuba. Vaccine. 2014;32(42):5399–404. doi:10.1016/j.vaccine.2014.07.109.
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis. 2012;205(2):237–43. doi:10.1093/infdis/jir723.
   PubMed Web of Science ®Google Scholar
• Okada K, Miyazaki C, Kino Y, Ozaki T, Hirose M, Ueda K. Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from Sabin strains (DTaP-sIPV). J Infect Dis. 2013;208(2):275–83. doi:10.1093/infdis/jit155.
   PubMed Web of Science ®Google Scholar
• Verdijk P, Rots NY, van Oijen MGCT, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WAM. Safety and immunogenicity of a primary series of Sabin-IPV with or without aluminium hydroxide in infants. Vaccine. 2014;32(39):4938–44. doi:10.1016/j.vaccine.2014.07.029.
   PubMed Web of Science ®Google Scholar
• Liao G, Li R, Li C, Sun M, Jiang S, Li Y, Mo Z, Xia J, Xie Z, Che Y, et al. Phase 3 trial of a Sabin strain–based inactivated poliovirus vaccine. J Infect Dis. 2016;214(11):1728–34. doi:10.1093/infdis/jiw433.
   PubMed Web of Science ®Google Scholar
• Nakano T, Sumino S, Takanami Y, Mitsuya N, Nakatome K. A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children. Hum Vaccin Immunother. 2018;14(12):2940–49. doi:10.1080/21645515.2018.1504538.
   PubMed Web of Science ®Google Scholar
• Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, Wang J, Li C, Zhang Q, Gao Q, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, dose-finding trial. Vaccine. 2018;36(45):6782–89. doi:10.1016/j.vaccine.2018.09.023.
   PubMed Web of Science ®Google Scholar
• Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34(16):1975–85. doi:10.1016/j.vaccine.2014.11.015.
   PubMed Web of Science ®Google Scholar
• Sanders BP, Edo-Matas D, Custers JHHV, Koldijk MH, Klaren V, Turk M, Luitjens A, Bakker WAM, Uytdehaag F, Goudsmit J, et al. PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. Vaccine. 2013;31(5):850–56. doi:10.1016/j.vaccine.2012.10.070.
   PubMed Web of Science ®Google Scholar
• Sanders BP, de Los Rios Oakes I, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JHHV, Macadam A, et al. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV. Vaccine. 2015;33(48):6611–16. doi:10.1016/j.vaccine.2015.10.091.
   PubMed Web of Science ®Google Scholar
• Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Vaccine. 2018;36(46):6979–87. doi:10.1016/j.vaccine.2018.09.068.
   PubMed Web of Science ®Google Scholar
• World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Accessed on 16 Jul 2020);310(20):2191–94. doi:10.1001/jama.2013.281053.
   PubMed Web of Science ®Google Scholar
• EMA. ICH good clinical practice guidelines. 2016 [accessed 2020 Jul 16]. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf.
   Google Scholar
• Food and Drug Administration. Center for biologics evaluation and research. guidance for industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007 Sept.
   Google Scholar
• World Health Organization. Expert committee on biological standardization (ECBS), sixty-fifth report. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (inactivated). WHO Technical Report Series No. 993, Annex 3, 2015.
   Google Scholar
• Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol. 2016;1387:145–76. doi:10.1007/978-1-4939-3292-4_8.
   PubMedGoogle Scholar
• KCE Report 313. Performance of the Belgian health system – report 2019. [accessed 2020 Jul 16] https://www.healthybelgium.be/metadata/hspa/p1_p2_p3.pdf.
   Google Scholar
• Murph JR, Grose C, McAndrew P, Mickiewicz C, Mento S, Cano F, Radick L, Ritchey M, Stout MG. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatric Infect Dis J. 1988;7(11):760–65. doi:10.1097/00006454-198811000-00003.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Expert committee on biological standardization Geneva, 29 October to 2 November 2018. Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV). 2018 [accessed 2020 Mar 16]. http://www.who.int/biologicals/BS.2018.2338_sIPV_IS_Collaborative_Study_Report_version.pdf.
   Google Scholar
• Sun M, Li C, Xu W, Liao G, Li R, Zhou J, Li Y, Cai W, Yan D, Che Y, et al. Immune serum from Sabin inactivated poliovirus vaccine immunization neutralizes multiple individual wild and vaccine-derived polioviruses. Clin Infect Dis. 2017;64(10):1317–25. doi:10.1093/cid/cix110.
   PubMed Web of Science ®Google Scholar